



IL RISCHIO CARDIOVASCOLARE NELLE DONNE

Dott.ssa Elisa Lodi

Prof.ssa Maria Grazia Modena



Medicina di Genere:
dal piano Nazionale alla clinica,
la salute delle differenze




PARADOSSO DONNA...

La donna vive più a lungo dell'uomo;

Quanto vivono gli italiani

Speranza di vita (anni) alla nascita

Maschi Femmine



Fonte: Osservasalute 2016

ANSA centimetri



.... alla longevità non corrisponde una miglior qualità di vita. Rispetto all'uomo...

**DAI DATI ISTAT:
Le donne hanno peggior
stato di salute degli uomini
(8.3% contro 5.3%)**

- Si ammala più frequentemente
- Manifesta più spesso sintomi dolorosi
- Entra con maggior frequenza in contatto con gli operatori sanitari

Allergie + 8%	Ipertensione +30%
Diabete + 9%	Malattie Tiroide + 500%
Cataratta + 80%	Osteoporosi + 736%
Depressione + 138%	Anoressia + 900%
Sindr.Metabolica + 200%	Alzheimer + 100%



EPPURE...


Fin dalle sue origini, la medicina ha avuto
un'impostazione androcentrica:



Medicina di Genere:
dal piano Nazionale alla clinica,
la salute delle differenze




IN REALTA'...



Differenze di sesso: cervello

Sex differences in the structural connectome of the human brain

Madhura Ingahalikar^{a,1}, Alex Smith^{a,1}, Drew Parker^a, Theodore D. Satterthwaite^b, Mark A. Elliott^c, Kosha Ruparel^b, Hakon Hakonarson^d, Raquel E. Gur^b, Ruben C. Gur^b, and Ragini Verma^{a,2}



I modelli di connettività del cervello **maschile** conferiscono ai maschi un sistema di coordinamento fra esperienze percettive e azione più efficiente, mentre i modelli di connettività dei cervelli **femminili** facilitano l'integrazione delle modalità di ragionamento analitico e sequenziale dell'emisfero sinistro con quelle spaziali e intuitive dell'emisfero destro.

Università della Pennsylvania a Filadelfia. ["Proceedings of the National Academy of Sciences"](#), Ragini Verma et al



Differenze di sesso: geni

Gershoni and Petrokovski *BMC Biology* (2017) 15:7
DOI 10.1186/s12915-017-0352-z

BMC Biology

RESEARCH ARTICLE

Open Access



The landscape of sex-differential transcriptome and its consequent selection in human adults

Moran Gershoni* and Shmuel Petrokovski

Donne e uomini sono geneticamente diversi per 6.500 motivi: i ricercatori hanno analizzato 20.000 geni di maschi e femmine e hanno scoperto che 6.500 di questi determinano alcune differenze tra i due sessi


Abstract

Background: The prevalence of several human morbid phenotypes is sometimes much higher than intuitively expected. This can directly arise from the presence of two sexes, male and female, in one species. Men and women have almost identical genomes but are distinctly dimorphic, with dissimilar disease susceptibilities. Sexually dimorphic traits mainly result from differential expression of genes present in both sexes. Such genes can be subject to different, and even opposing, selection constraints in the two sexes. This can impact human evolution by differential selection on mutations with dissimilar effects on the two sexes.

Results: We comprehensively mapped human sex-differential genetic architecture across 53 tissues. Analyzing available RNA-sequencing data from 544 adults revealed thousands of genes differentially expressed in the reproductive tracts and tissues common to both sexes. Sex-differential genes are related to various biological systems, and suggest new insights into the pathophysiology of diverse human diseases. We also identified a significant association between sex-specific gene transcription and reduced selection efficiency and accumulation




Differenze di sesso: geni



Numero di geni espressi in modo differente in maschi e femmine in 45 tessuti comuni a entrambi i sessi. (Cortesia M. Gershoni, S. Pietrokovski/BCM Biology)

**Il genoma di base è più o meno lo stesso per tutti ,
ma è utilizzato in maniera diversa dal corpo a seconda degli individui.**





The New England Journal of Medicine

Owned and Published by the
Massachusetts Medical Society

Philip E. McCarthy, M.D.
President

William M. McDermott, Jr., M.D.
Executive Vice President

Charles S. Amoroso, Jr.
Executive Secretary

THE COMMITTEE ON PUBLICATIONS
OF THE MASSACHUSETTS MEDICAL SOCIETY

James E. McDonough, M.D., *Chairman*


OF THE MASSACHUSETTS MEDICAL SOCIETY
THE COMMITTEE ON PUBLICATIONS


THE YENTL SYNDROME


YENTL, the 19th-century heroine of Isaac Bashevis Singer's short story,¹ had to disguise herself as a man to attend school and study the Talmud. Being "just like a man" has historically been a price women have had to pay for equality. Being different from men has meant being second-class and less than equal for most of recorded time and throughout most of the world. It may therefore be sad, but not surprising, that women have all too often been treated less than equally in social relations, political endeavors, business, education, research, and health care.

From research and health care
social relations, political endeavors, business, educa-
tion, research, and health care.









INOLTRE...



La comunità ha sempre guardato alla salute della donna con un approccio a 'bikini', considerando essenzialmente solo il **seno e il sistema riproduttivo**, vale a dire ignorando quasi totalmente il resto dell'organismo femminile nell'ambito dei problemi di salute

Nanette Wenger, MD

2001: PBS documentary "A Woman's Heart"

IL MITO

La coronaropatia è una patologia prettamente maschile



LA REALTA'

APRIL 28, 2003

www.time.com AOL Keyword: TIME

100 - HOW THE OCCUPATION / THE COUNTRY FOR AGING

49%

PATOLOGIE
DEL SISTEMA
CARDIO-CIRCOLATORIO



26%

PATOLOGIE
UMORALI



5,6%

DISTURBI
PSICHICI



5,6%

PATOLOGIE
RESPIRATORIE



5,6%

ALTRE
PATOLOGIE




4,5%

PATOLOGIE
APPARATO
DIGERENTE



WHO KNEW?



80% AMERICAN WOMEN DID NOT




Figura 29. Le malattie cardiovascolari (MCV) nella donna.

FATTORE DI RISCHIO:

Definizione:

tutto ciò che aumenta in maniera statisticamente significativa la probabilità di sviluppare una certa patologia.





Medicina di Genere:
dal piano Nazionale alla clinica,
la salute delle differenze

- Condizioni statisticamente correlate all'insorgenza di una malattia cardiovascolare che, se presenti in un soggetto

Effetto SINERGICO

ASSENZA $\neq$ ESCLUSIONE
MALATTIA





FATTORI DI RISCHIO

TRADIZIONALI

(fattori di rischio
FRAMINGHAM)

NON MODIFICABILI

non suscettibili di una possibile
correzione tramite misure preventive
o interventi farmacologici




ETA'

SESSO

FAMILIARITA'

FATTORI DI RISCHIO



TRADIZIONALI

(fattori di rischio
FRAMINGHAM)



MODIFICABILI

Legati allo stile di vita e suscettibili di una
possibile correzione tramite misure
preventive o interventi farmacologici

- 
- Fumo di sigaretta
 - Obesità e inattività fisica
 - Diabete
 - Ipertensione arteriosa
 - Dislipidemie
 - IRC



COMUNI ... MA DIVERSI *PESO DI RISCHIO*

Research

Sex differences in risk factors for myocardial infarction: cohort study of UK Biobank participants


BMJ 2018 ; 363 doi: <https://doi.org/10.1136/bmj.k4247> (Published 07 November 2018)

Cite thi

Results 5081 participants (1463 (28.8%) of whom were women) had MI over seven years' mean follow-up, resulting in an incidence per 10 000 person years of 7.76 (95% confidence interval 7.37 to 8.16) for women and 24.35 (23.57 to 25.16) for men. Higher blood pressure indices, smoking intensity, body mass index, and the presence of diabetes were associated with an increased risk of MI in men and women, but associations were attenuated with age. In women, systolic blood pressure and hypertension, smoking status and intensity, and diabetes were associated with higher hazard ratios for MI compared with men: ratio of hazard ratios 1.09 (95% confidence interval 1.02 to 1.16) for systolic blood pressure, 1.55 (1.32 to 1.83) for current smoking, 2.91 (1.56 to 5.45) for type 1 diabetes, and 1.47 (1.16 to 1.87) for type 2 diabetes. There was no evidence that any of these ratios of hazard ratios decreased with age ($P>0.2$). With the exception of type 1 diabetes, the incidence of MI was higher in men than in women for all risk factors.

Conclusions Although the incidence of MI was higher in men than in women, several risk factors were more strongly associated with MI in women compared with men. Sex specific associations between risk factors and MI declined with age, but, where it occurred, the higher relative risk in women remained. As the population ages and the prevalence of lifestyle associated risk factors increase, the incidence of MI in women will likely become more similar to that in men.






FRCV EMERGENTI PREDOMINANTI NELLE DONNE

Le malattie autoimmuni

- sono condizioni caratterizzate da una risposta **impropria** ed **esagerata** del sistema immunitario.
- tendono a colpire prevalentemente il **sexo femminile** (la prevalenza è da 2 a 50 volte superiore nella donna rispetto all'uomo) visto il ruolo immunostimolante esercitato dagli estrogeni



Malattie Autoimmuni

Crescenti evidenze suggeriscono che i pazienti affetti da alcune malattie autoimmuni abbiano un incrementato rischio di morbidità e mortalità CV,

CURIOSITA':

Il LES pare ad oggi la malattia autoimmune con maggiore rischio CV, il rischio di CVD è **4-8 volte superiore** rispetto alla popolazione generale

(P.C. Teixeira, et al.)

- Questo fenomeno è stato descritto per la prima volta intorno agli anni '50 in pazienti con LES.


CURIOSITA'

L'AR si associa a **una diminuzione di 10-15 anni della aspettanza di vita** nei confronti della popolazione general. Circa la **metà di tutte le morti nei pazienti con AR sono riconducibili a cause cardiovascolari.**



FRCV EMERGENTI PREDOMINANTI NELLE DONNE

Depressione e stress psicologico: i nuovi killer silenziosi



"For every affection of the mind that is attended with either pain or pleasure, hope or fear, is the cause of an agitation whose influence extends to the heart."



Relation between resting amygdalar activity and cardiovascular events: a longitudinal and cohort study

THE LANCET

Log in Register Subscribe

Juynh A Truong,
Udo Hoffmann,

FAST TRACK — ARTICLES | VOLUME 364, ISSUE 9438, P953-962, SEPTEMBER 11, 2004

Subscribe Save Share

Association of psychosocial risk factors with risk of acute myocardial infarction in 11 119 INTERHEART study

Prof Annika Rosengren, MD - St
Mohammad Zubaid, MD - Wael

Published: September 11, 2004

e. We imaged the amygdala,

Circulation

MY ALERTS

SIGN IN

Submit your article

AHA Journals Journal Information All Issues Subjects Features Resources & Education For Authors & I

This site uses cookies. By continuing to browse this site you are agreeing to our use of cookies.

Click here for more information.

second corrected version
appeared on February 23, 2017.

See [Comment](#) page 770

*These authors contributed
equally

†These authors contributed

between
and card
amygdala
(path) an

Findings

Home > Circulation > Vol. 129, No. 12 > Depression as a Risk Factor for Poor Prognosis Among Patients With Acute Coronary

Subscribe

Log In

Basket

search

Search

nces
Ac
se

BMJ Journals

Heart

Home / Archive / Volume 103, Issue 23

Latest content

Current issue

Archive

Authors

Podcasts

En

Article
Text

Article
Info

Citation
Tools

Editorial

Psychological distress and mortality in stable coronary heart disease: persistence of high distress means increased risk

Gjin Ndrepepa

Correspondence to

Dr Gjin Ndrepepa, Department of Adult Cardiology, Deutsches Herzzentrum München, Technical University, Munich 80636, Germany;

ndrepepa@dhm.mhn.de




Mechanisms by which depression may lead to cardiac events and mortality

BEHAVIOURAL MECHANISMS

- Dietary factors
- Lack of exercise
- Medication non-adherence
- Poor social support
- Unhealthy lifestyle



BIOLOGICAL MECHANISMS



European Heart Journal (2003) 24, 2027–2037




Clinical research




Depression and cardiovascular morbidity and mortality: cause or consequence?

Ralph A. H. Stewart^{a,f*}, Fiona M. North^b, Teena M. West^a, Katrina J. Sharples^b, R. John Simes^c, David M. Colquhoun^{d,e}, Harvey D. White^{a,e}, Andrew M. Tonkin^{g,h,1}, for the Long-Term Intervention With Pravastatin in Ischaemic Disease (LIPID) Study Investigators





FATTORI DI RISCHIO SPECIFICI PER LE DONNE:



```
graph TD; A[FATTORI DI RISCHIO SPECIFICI PER LE DONNE] --> B[LEGATI ALLA GRAVIDANZA]; A --> C[ORMONALI]; A --> D[ALTRI];
```

LEGATI ALLA
GRAVIDANZA

ORMONALI

ALTRI



Medicina di Genere:
dal piano Nazionale alla clinica,
la salute d

Menarca precoce e tardivo

Circulation

[AHA Journals](#)
[Journal Information](#)
[All Issues](#)
[Subjects](#)
[Features](#)
[Resources](#)

Home > Circulation > Vol. 131, No. 3 > Age at Menarche and Risks of Coronary Heart and Other Vascular Diseases in a Large Cohort

FREE ACCESS

ARTICLE

Download PDF


Tools Share

Age at Menarche and Other Vascular Disease in a Large Cohort

Dexter Canoy, Valerie B. Liss, Mary E. Kroll, Gillian K. Rosman, and for the Million Women Study

Conclusions—

In this cohort, the relation of age at menarche to vascular disease risk was U shaped, with both early and late menarche being associated with increased risk. Associations were weaker for cerebrovascular and hypertensive disease than for CHD.





Original Investigation

FREE

October 2016

Association of Age at Onset of Menopause and Time Since Onset of Menopause With Cardiovascular Outcomes, Intermediate Vascular Traits, and All-Cause Mortality

A Systematic Review and Meta-analysis

Taulant Muka, MD, PhD¹; Clare Oliver-Williams, PhD²; Setor Kunutsor, MD, PhD²; et al

Findings In this meta-analysis of 32 observational studies, premature or early-onset menopause in women younger than 45 years were associated with an increased risk of coronary heart disease and all-cause mortality. Time since onset of menopause in relation to vascular outcomes was reported in 4 studies and showed inconsistent results.

Meaning Our findings underscore a potential increased risk of adverse cardiovascular outcomes in women who experience premature or early-onset menopause.

Menopausa precoce (POF)

scomparsa dei cicli mestruali ad un'età < 45 anni




La menopausa:	
	FAVOREVOLE
Lipidi	↓ Colesterolo LDL ↑ Colesterolo HDL
Coagulazione	↓ Fibrinogeno
Infiammazione	↓ Molecole di adesione
Funzione endoteliale e pressione arteriosa	↓ Attività dell' enzima ACE ↑ Sintesi Ossido Nitrico ↓ Endotelina-1 ↓ Proliferazione delle cellule muscolari lisce

(Sindrome dell'ovaio policistico)

La PCOS è diagnosticata in presenza di due tra i tre criteri seguenti:


1. ovaie policistiche all'ecografia pelvica
2. oligo-anovulazione
3. evidenza clinica o biochimica di iperandrogenismo

(Rotterdam ESHRE-ASRM 2003)




PCOS

(Sindrome dell'ovaio policistico)



FATTORI DI RISCHIO SPECIFICI PER LE DONNE:



```
graph TD; A[FATTORI DI RISCHIO SPECIFICI PER LE DONNE] --> B[LEGATI ALLA GRAVIDANZA]; A --> C[ORMONALI]; A --> D[ALTRI];
```

LEGATI ALLA
GRAVIDANZA

ORMONALI

ALTRI



Medicina di Genere:
dal piano Nazionale alla clinica,
la salute d

FR specifici per donne legati alla gravidanza



ABORTO SPONTANEO – maggiore rischio di infarto miocardico nel corso della loro vita, gli aborti ricorrenti possono essere associati a stati procoagulanti e proinfiammatori.

PARTO PRETERMINE - Le donne che hanno avuto un parto naturale prima delle 37 settimane di gestazione, sembrano avere un maggiore rischio di malattia CV

IPERTENSIONE GESTAZIONALE, PRE-ECLAMPISIA (ipertensione, proteinuria e/o edemi) **ED ECLAMPISIA** (convulsioni generalizzate dovute ad encefalopatia associata a pre-eclampsia) aumenta il rischio di sviluppare ipertensione post-partum, infarto miocardico ed ictus ed aumenta di 4 volte il rischio di sviluppare diabete tipo 2; inoltre, i figli di madre con pre-eclampsia hanno un rischio > di sviluppare ipertensione arteriosa

DIABETE IN GRAVIDANZA - le donne che sviluppano DG hanno un rischio 7 volte più elevato di sviluppare DM di tipo 2, inoltre, aumenta anche il rischio di malattia CV indipendentemente dallo sviluppo di diabete manifesto. I figli nati da madri con DG hanno a loro volta un rischio maggiore di andare incontro ad intolleranza glucidica.



FATTORI DI RISCHIO SPECIFICI PER LE DONNE:

```
graph TD; A[FATTORI DI RISCHIO SPECIFICI PER LE DONNE] --> B[LEGATI ALLA GRAVIDANZA]; A --> C[ORMONALI]; A --> D[TUMORE AL SENO];
```

LEGATI ALLA
GRAVIDANZA

ORMONALI

TUMORE
AL SENO



Medicina di Genera
dal piano Nazionale alle clin
la salute d



Circulation

AHA SCIENTIFIC STATEMENT

Cardiovascular Disease and Breast Cancer: Where These Entities Intersect

A Scientific Statement From the American Heart Association

ABSTRACT: Cardiovascular disease (CVD) remains the leading cause of mortality in women, yet many people perceive breast cancer to be the number one threat to women's health. CVD and breast cancer have several overlapping risk factors, such as obesity and smoking. Additionally, current breast cancer treatments can have a negative impact on cardiovascular health (eg, left ventricular dysfunction, accelerated CVD), and for women with pre-existing CVD, this might influence cancer treatment decisions by both the patient and the provider. Improvements in early detection and treatment of breast cancer have led to an increasing number of breast cancer survivors who are at risk of long-term cardiac complications from cancer treatments. For older women, CVD poses a greater mortality threat than breast cancer itself. This is the first scientific statement from the American Heart Association on CVD and breast cancer. This document will provide a comprehensive overview of the prevalence of these diseases, shared risk factors, the cardiotoxic effects of therapy, and the prevention and treatment of CVD in breast cancer patients.

Laxmi S. Mehta, MD,
FAHA, Chair
Karol E. Watson, MD, PhD,
FAHA, Vice Chair
Ana Barac, MD, PhD
Theresa M. Beckie, PhD,
FAHA
Vera Bittner, MD, MSPH,
FAHA
Salvador Cruz-Flores, MD,
MPH, FAHA
Susan Dent, MD
Lavanya Kondapalli, MD
Bonnie Ky, MD, MSCE
Tochukwu Okwuosa, DO
Ileana L. Piña, MD, MPH,
FAHA
Annabelle Santos Volgman,
MD, FAHA



CHEMIOTERAPIA



European Heart Journal (2016) 37, 2768–2801
doi:10.1093/eurheartj/ehw211

ESC CPG POSITION PAPER

2016 ESC Position Paper on cancer treatments and cardiovascular toxicity developed under the auspices of the ESC Committee for Practice Guidelines

The Task Force for cancer treatments
the European Society of Cardiology

Authors/Task Force Members: Jose L. Zamora (Spain), Patrizio Lancellotti* (Co-Chairperson, Italy), Victor Aboyans (France), Riccardo A. de Boer (Netherlands), Gilbert Habib (France), Daniel J. Lennon (UK), Alexander R. Lyon (UK), Teresa Lopez-Vale (Spain), Massimo F. Piepoli (Italy), Juan Tamargo (Spain), Thomas M. Suter (Switzerland)

ESC Committee for Practice Guidelines (CPG): Jos van Boven (Netherlands), Stephan Achenbach (Germany), Stefan Agewall (Norway), Helmut Baumgartner (Germany), Jeroen J. Bax (The Netherlands), Veronica Dean (France), Çetin Erol (Turkey), Don Paulus Kirchhof (UK/Germany), Philippe Kolh (Belgium), Petros Nihoyannopoulos (UK), Massimo F. Piepoli (Italy), Adam Torbicki (Poland), António Vaz Carneiro (Portugal)

Chemotherapy agents	Dose (mg/m ²)
Anthracyclines (dose dependent)	
Doxorubicin (Adriamycin)	
400 mg/m ²	3–5
550 mg/m ²	7–26
700 mg/m ²	18–48
Idarubicin (>90 mg/m ²)	5–18
Epirubicin (>900 mg/m ²)	0.9–11.4
Mitoxantrone >120 mg/m ²	2.6
Liposomal anthracyclines (>900 mg/m ²)	2
Antimetabolites	
Cyclophosphamide	7–28
Ifosfamide	
<10 g/m ²	0.5
12.5–16 g/m ²	17
Antimetabolites	
Clofarabine	27





RADIOTERAPIA

The NEW ENGLAND JOURNAL of MEDICINE

ESTABLISHED IN 1812

MARCH 14, 2013

VOL. 368 NO. 11

Risk of Ischemic Heart Disease in Women after Radiotherapy for Breast Cancer

Sarah C. Darby, Ph.D.,
Ulla Blom-Goldman, M.
Giovanna Gagliardi, Ph.D.,
Richard Peto, F.R.C.

BACKGROUND

Radiotherapy for breast cancer or to ionizing radiation. The effect on heart disease is uncertain.

METHODS

We conducted a population-based study of myocardial infarction, coronary disease) in 2168 women who were treated with radiotherapy between 1958 and 2001 in Sweden and Denmark. We used data from hospital records. For each woman, we calculated the mean dose to the heart and the left anterior descending artery. We used a Poisson regression model to estimate the rate of major coronary events per gray (95% confidence interval).

RESULTS

The overall average of the mean dose to the heart was 27.72 Gy. Rates of major coronary events increased by 7.4% per gray (95% confidence interval 2.9 to 14.5). The increase in the rate of major coronary events was greater for women without cardiac risk factors than for women with cardiac risk factors.

CONCLUSIONS

Exposure of the heart to ionizing radiation increases the subsequent rate of major coronary events in a dose-dependent manner. The increase in the rate of major coronary events continues for at least 20 years after treatment. Greater absolute increases in risk were seen in women without cardiac risk factors than in women with cardiac risk factors. Cancer Research UK and others.




Figure 1. Rate of Major Coronary Events According to Mean Radiation Dose to the Heart, as Compared with the Estimated Rate with No Radiation Exposure to the Heart.

Major coronary events included myocardial infarction, coronary revascularization, and death from ischemic heart disease. The values for the solid line were calculated with the use of dose estimates for individual women. The circles show values for groups of women, classified according to dose categories; the associated vertical lines represent 95% confidence intervals. All estimates were calculated after stratification for country and for age at breast-cancer diagnosis, year of breast-cancer diagnosis, interval between breast-cancer diagnosis and first major coronary event for case patients or index date for controls (all in 5-year categories), and presence or absence of a cardiac risk factor. The radiation categories were less than 2, 2 to 4, 5 to 9, and 10 Gy or more, and the overall averages of the mean doses to the heart of women in these categories were 1.4, 3.4, 6.5, and 15.8 Gy, respectively.

enmet, Ph.D.,
Jetter, F.R.C.R.,
Visbet, Ph.D.,
Il, Ph.D.

Clinical Trial Service Unit, M., D.C., R.P., C.T.) and the Centre for Healthcare Innovation, University of Oxford, Oxford, and the Department of Medical Physics, Royal Marsden Hospital and Surrey University (A.N.) — both in the United Kingdom; the Department of Oncology, University Hospital, Institute of Radiation Physics, University of South Denmark, Odense (M.E.); the Oncology, Aarhus Hospital, Aarhus, Denmark; the Danish Breast Cancer Cooperative Group, Rigshospitalet, Copenhagen (M.B.); all in Denmark; the Department of Medical Epidemiology and Biostatistics (A.M.B., Ph.D.), Division of Cardiovascular Epidemiology, Department of Environmental Medicine, Division of Cardiovascular Medicine, Department of Clinical Science, Karolinska Hospital (B.G.), Karolinska University Hospital — Huddinge, and the H. Lee Moffitt Cancer Center and Research Institute, University of South Florida, Tampa (J.M.). Reprint requests to Dr. Darby: Clinical Trial Service Unit, 18 Bldg., Old Road Campus, 37L, United Kingdom, or at s.darby@ox.ac.uk.

(2013)368:987-96.
doi:10.1056/NEJMoa1208825

© 2013 Massachusetts Medical Society

Il tasso di eventi coronarici aumenta del 7,4% per ogni aumento di 1 Gy della dose di radiazione



Medi
dal p
la sal



*Prevenire è meglio che curare...
ma per prevenire bisogna conoscere*




Figura 32. Algoritmo per la prevenzione cardiovascolare nelle donne.



**La Donna vive di più,
ma con maggiori comorbilità, che condizionano la sua qualità di vita.**

Occorrono maggiori conoscenze, più sensibilità

e mirati programmi di prevenzione

per rendere la vita delle Donne

Età di Serenità

piuttosto che era di malattie

e di invalidità



Medicina di Genere:
dal piano Nazionale alla clinica,
la salute delle differenze



***Buona prevenzione
e grazie per l'attenzione!***





Medicina di Genere:
dal piano Nazionale alla clinica,
la salute delle differenze

TERAPIA ORMONALE

Effettuata per i tumori ER e/o PR positivi include

- Tamoxifene nelle donne in pre-menopausa
- inibitori dell'aromatasi in quelle i post-menopausa

Diversi studi hanno evidenziato un trend verso una maggiore incidenza di tossicità CV degli **inibitori dell'aromatasi** rispetto al Tamoxifene che, avendo un impatto favorevole sul profilo lipidico, ha un effetto cardioprotettivo.

